RIGVIR® mechanism of action

RIGVIR® against cancer

RIGVIR® - the world’s first oncolytic virotherapy medicine that has been approved for cancer treatment and introduced into medical practice. RIGVIR® contains a live non-pathogenic ECHO-7 virus that has not been genetically modified.

RIGVIR® is an oncotropic and oncolytic virus. It finds and selectively infects tumour cells. The virus then replicates in tumour cells and destroys them. Both of these processes, oncotropism and oncolysis, are selective for tumour cells and healthy cells are only minimally affected, if at all.

Oncolytic virotherapy with RIGVIR® is a safe and effective cancer treatment, which improves progression time, survival and the quality of life of cancer patients.



  1. Oncotropic and oncolytic virus
  2. Safe and effective
  3. Live and nonpathogenic
  4. Genetically not modified
  5. Ambulatory use
  6. Well tolerated

European Commission within a framework of Horizon 2020 programme awarded RIGVIR manufacturer Latima with a grant for cancer virotherapy medicine commercialization in the EU markets.

www.virotherapy.eu is a global virotherapy website, where you can find more information about virotherapy, history of Rigvir discovery, educational courses in virotherapy and cooperation possibilities.